A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification
Authors:
- Peter LeePLPeter Lee
- Tatiana PlavinaTPTatiana Plavina
- Albert CastroACAlbert Castro
- Melissa BermanMBMelissa Berman
- Dipeshkumar JaiswalDJDipeshkumar Jaiswal
- Suzanne RivasSRSuzanne Rivas
- Brian SchlainBSBrian Schlain
- Meena SubramanyamMSMeena Subramanyam
- 1 June 2013
- journal article
- research article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 57 (2) , 141-146
Abstract
No abstract availableKeywords
Funding Information
- Biogen Idec Inc.
- Elan Pharmaceuticals, Inc.
This publication has 8 references indexed in Scilit:
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasmaJournal of Clinical Virology, 2012
- Progressive Multifocal Leukoencephalopathy and Newer Biological AgentsDrug Safety, 2010
- Anti‐JC virus antibodies: Implications for PML Risk StratificationAnnals of Neurology, 2010
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory TherapiesAnnual Review of Medicine, 2010
- Seroepidemiology of Human PolyomavirusesPLOS Pathogens, 2009
- Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40Journal of Medical Virology, 2003
- Seroepidemiology of the human polyomavirusesJournal of General Virology, 2003